Intra-operative iodine-125 prostatic implant following bilateral pelvic lymphadenectomy.
Sixty-five patients with prostatic adenocarcinoma Stages B and C were treated with intraoperative Iodine-125 prostatic implantation following bilateral pelvic lymphadenectomy. Pelvic nodal metastases were found in 31% of the patients: 23% (7/31) in clinical Stage B1 disease, 29% (8/28) in clinical Stage B2, and 83% (5/6) in clinical Stage C. All the patients have been followed for a period of 1 1/2 to 6 years. Serial digital rectal examination revealed complete regression of the palpable disease in 15% of the patients at 6 months, 47% at 1 year, and 87% at 2 years. Post-operative complications were also evaluated: 13% of the patients became sexually impotent, 11% had impaired potency after the procedure, and 16% of patients complained of dry ejaculation; and 17% developed scrotal and/or penile swelling, which persisted up to 14 months, but usually subsided within 5 months. Two patients developed local recurrence. Both patients responded to subsequent external radiation therapy of 7000 rad in 11 to 14 weeks with clinical regression of palpable disease.
D000230:Adenocarcinoma / Q000532:radiotherapy* / Q000601:surgery; D000368:Aged; D001918:Brachytherapy; D003131:Combined Modality Therapy; D006801:Humans; D007432:Intraoperative Period; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010388:Pelvis; D011471:Prostatic Neoplasms / Q000532:radiotherapy* / Q000601:surgery
D007457:Iodine Radioisotopes